• About us
• Contact

Advertisement

Organisation › Details

Johnson & Johnson (JnJ) (Group)

Johnson & Johnson is the world's most comprehensive and broadly based manufacturer of health care products, as well as a provider of related services, for the consumer, pharmaceutical, and medical devices and diagnostics markets. The more than 250 Johnson & Johnson operating companies employ approximately 121,000 men and women in 57 countries and sell products throughout the world. *

 

	Start	1888-01-01 established?
	Industry	pharmaceutical
	Industry 2	diagnostics (medical/biological)
	Person	Gorsky, Alex (JnJ 201701 CEO before 200811 Group Chairman for Ethicon business worldwide)
	Region	New Brunswick, NJ
	Country	United States (USA)
	Street	One Johnson & Johnson Plaza
	City	08933 New Brunswick, NJ
		Address record changed: 2020-12-02
Basic data	Employees	J: more than 100,0 (2017-01-26)
	Currency	USD
	Annual sales	82,584,000,000 (sales, consolidated (2020) 2020-12-31)
		* Document for »About Section«:
		Record changed: 2023-07-10

Advertisement

More documents for Johnson & Johnson (JnJ) (Group)

• [1] Addex Therapeutics S.A.. (4/29/24). "Press Release: Addex Provides Update on ADX71149 Phase 2 Epilepsy Study". Geneva....
• [2] Basel Area Business & Innovation. (4/26/24). "Press Release: Johnson & Johnson Opens Innovation Hub in Allschwil"....
• [3] Asgard Therapeutics AB. (3/14/24). "Press Release: Asgard Therapeutics Announces €30 Million Series A Financing to Advance Its First-in-Class in vivo Cell Reprogramming Platform for Immuno-oncology". Lund....
• [4] Johnson & Johnson. (1/8/24). "Press Release: Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer". New Brunswick, NJ....
• [5] Sanofi S.A.. (10/3/23). "Press Release: Sanofi Announces Agreement for Potential First-in-Class Vaccine against Extraintestinal Pathogenic E. coli". Paris....
• [6] Nanobiotix S.A.. (7/10/23). "Press Release: Nanobiotix Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3". Paris & Cambridge, MA....
• [7] Alia Therapeutics S.r.l.. (5/5/23). "Press Release: Alia Therapeutics Names Letizia Goretti as Chief Executive Officer". Milan....
• [8] Evotec SE. (1/26/23). "Press Release: Evotec Announces Agreement with Janssen to Develop Immune-based Therapies". Hamburg....
• [9] Evotec SE. (6/14/22). "Press Release: Evotec Enters a Drug Discovery Collaboration with Janssen". Hamburg....
• [10] Nouscom AG. (5/17/22). "Press Release: Nouscom Announces Janssen Receives US FDA IND Clearance for VAC85135, an ‘Off-The-Shelf’ Cancer Immunotherapy Developed using Nouscom’s Proprietary Viral Vector Platform". Basel....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.